TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Precision BioSciences ( (DTIL) ) just unveiled an announcement.
On November 10, 2025, Precision BioSciences, Inc. announced an underwriting agreement with Guggenheim Securities, LLC for the sale of 10,815,000 shares of common stock and accompanying warrants, expecting to raise approximately $70 million. The proceeds will be used for research and development, working capital, and other corporate purposes, with the offering’s closing anticipated on November 12, 2025, subject to customary conditions.
The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.
Spark’s Take on DTIL Stock
According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, characterized by declining revenues and significant losses. Technical analysis provides a slightly more positive outlook with some bullish momentum, but valuation remains a concern due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on DTIL stock, click here.
More about Precision BioSciences
Precision BioSciences, Inc. operates in the biotechnology industry, focusing on the development and commercialization of gene editing technologies. The company primarily offers products and services related to the research and development of genetic therapies, aiming to address various genetic disorders and improve healthcare outcomes.
Average Trading Volume: 141,117
Technical Sentiment Signal: Hold
Current Market Cap: $80.47M
For detailed information about DTIL stock, go to TipRanks’ Stock Analysis page.